The PurpleLab^® Resource Center

The healthcare landscape is more complex than ever – and pharmaceutical companies are feeling the pressure. From pre-commercial drug development to post-launch performance, success hinges on a deep understanding of the full patient journey. However, traditional approaches to patient mapping often miss the nuanced factors that shape real-world health outcomes. Enter real-world data (RWD) enriched…

Cancer survival rates have improved dramatically over the past few decades thanks to ongoing advances in therapeutics. As research continues to push the boundaries of medicine, two innovative technologies stand out in the fight against cancer: Antibody-Drug Conjugates (ADCs) and PROteolysis TArgeting Chimeras (PROTACs). These cutting-edge approaches are refining how we treat cancer and opening…

For all the buzz around the Inflation Reduction Act (IRA), opinions on its impact are sharply divided – especially in the life sciences sector. Critics argue that the IRA’s drug pricing provisions, particularly Medicare price negotiation, will stifle innovation by reducing incentives for pharmaceutical companies to invest in research and development.  But these concerns don’t…